Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serplulimab Combined With NabPE for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast Cancer- A Single-arm, Multicenter, Phase 2 Clinical Study

NCT06394661 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06394661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06394661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serplulimab Combined With NabPE for Early-stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Breast Cancer- A Single-arm, Multicenter, Phase 2 Clinical Study
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 28, 2024
Completion date
December 30, 2028
Enrollment
109 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer